PLUS1
3.40
-0.13 (-3.68%)
-0.13 (-3.68%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Akers Biosciences Inc | AKER | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.13 | -3.68% | 3.40 | 09:07:15 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.53 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 3.40 | 3.52 | 0.12 | - | - |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 17 | 1,153 | 438,363 | 1.55 - 8.85 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:08:01 | 17 | $ 3.40 | USD |
Akers Biosciences Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 63.33M | 18.63M | 18.62M | $ 1.58M | $ - | -6.35 | -0.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Akers Biosciences News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/23/2021 | 09:00 | Business Wire | MyMD Pharmaceuticals Announces New Data on Its Lead Compound.. |
| 2/18/2021 | 14:23 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) |
| 2/18/2021 | 09:01 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in.. |
| 2/18/2021 | 09:00 | Business Wire | Study Identifies Effects of Temperature Changes on.. |
| 2/17/2021 | 13:45 | Business Wire | Akers Biosciences Responds to Erroneous Earnings Call Press.. |
| 2/17/2021 | 10:57 | Seeking Alpha | Onconova Therapeutics, Processa Pharmaceuticals leads.. |
| 2/11/2021 | 18:00 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AKER Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.89 | 4.08 | 2.73 | 3.59 | 693,300 | -0.49 | -12.6% |
| 1 Month | 2.85 | 5.22 | 2.58 | 4.08 | 1,706,973 | 0.55 | 19.3% |
| 3 Months | 1.99 | 5.22 | 1.935 | 3.47 | 872,464 | 1.41 | 70.85% |
| 6 Months | 4.00 | 5.22 | 1.65 | 2.68 | 1,205,057 | -0.60 | -15.0% |
| 1 Year | 3.26 | 8.85 | 1.55 | 3.78 | 1,456,559 | 0.14 | 4.29% |
| 3 Years | 0.53 | 8.85 | 0.20 | 1.37 | 2,093,928 | 2.87 | 541.51% |
| 5 Years | 1.68 | 8.85 | 0.122 | 1.05 | 1,910,698 | 1.72 | 102.38% |
Akers Biosciences Description
| Akers Biosciences Inc is engaged in developing, manufacturing and supplying rapid, point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician in a time- and cost-efficient manner. The pipeline products of the company focus on delivering diagnostic assistance in a variety of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious disease detection. The majority of the company's revenue comes from the United States. |
